Nasdaq

Targovax announces that the ONCOS-102 and durvalumab trial successfully completes part 1 in colorectal cancer

- The pre-defined disease control efficacy threshold in ovarian cancer was not met and this cohort will be closed for enrollment OSLO, Norway, Oct. 13, 2020 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a ...
Yahoo Finance

ONCOS-102: An Oncolytic Adenovirus with an Immune-Stimulating Transgene - Emerging Drug Analysis and Market Forecasts, 2019-2023 and 2023-2032 with Focus on 7 Major Markets

Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "ONCOS-102 Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. This report provides ...
ascopubs.org

Study to evaluate intraperitoneal (IP) ONCOS-102 with systemic durvalumab in patients with peritoneal disease who have epithelial ovarian (OC) or metastatic colorectal cancer ...

This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This abstract does not include a full text component.
Medindia

Targovax ASA: ONCOS-102 achieves 25.0 months median overall survival in first line mesothelioma

OSLO, Norway, Dec. 20, 2021 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical-stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces mOS of ...
Nasdaq

Targovax Announces Encouraging Results From Part 1 of the ONCOS-102 and Keytruda Combination Trial in Anti-PD1 Refractory Melanoma

OSLO, Norway, July 8, 2019 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing oncolytic viruses to target hard-to-treat solid tumors, today announces that ...
Business Insider

Targovax receives Fast Track designation for ONCOS-102 in melanoma

-The US FDA grants ONCOS-102 Fast Track designation for PD-1-refractory advanced melanoma -Fast Track designation further strengthens the opportunity for accelerated approval for ONCOS-102 in melanoma ...
FierceBiotech

Targovax to merge with Oncos then IPO in push for immuno-oncology mainstream

Targovax is to merge with fellow Nordic biotech Oncos Therapeutics to create an immuno-oncology player with the critical mass to get noticed in the congested and fiercely fought field. The merged ...
GEN

Oncos Raises €4M to Progress Lead Adenovirus Candidate into Formal Clinical Trials

Individually tailored oncolytic virus therapy has been tested in 200 late-stage cancer patients and 18 tumor types. Oncos Therapeutics completed a €4 million (about $5.29 million) fundraising with ...
technologynetworks

Oncos Therapeutics Raises €4 Million from Healthcap to Develop Oncolytic Viruses into Cancer Treatments

Oncos Therapeutics, a biotech company developing new cancer therapeutics based on its next generation oncolytic viruses, completed a € 4 million ($ 5.5 million) investment from HealthCap. With ...
ascopubs.org

Phase I/II study to evaluate systemic durvalumab + intraperitoneal (IP) ONCOS-102 in patients with peritoneal disease who have epithelial ovarian (OC) or metastatic colorectal ...

Pharmacodynamic, safety, and efficacy results of a phase I/II trial of intratumoral INT230-6 alone (IT-01) or in combination with pembrolizumab (PEM) (Keynote A10) in patients with advanced solid ...
Business Insider

Targovax receives Fast Track designation for ONCOS-102 in melanoma

OSLO, Norway, June 22, 2021 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage immune-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that ...